Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

63 results about "New chemical entity" patented technology

A new chemical entity (NCE) is, according to the U.S. Food and Drug Administration, a drug that contains no active moiety that has been approved by the FDA in any other application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act.

Polyisoprenylated Benzophenones and Their Isomers as Inhibitors of Histone Acetyltransferases and Uses thereof

In this patent we describe the purification of prenylated benzophenones from the fruit rinds of Garcinia species and its evaluation as an inhibitor for Histone acetyltransferases p300 and PCAF. We have found that prenylated benzophenones are potent HAT inhibitors of p300 (IC50-1 μM) and pCAF (IC50-15 μM). The inhibitors significantly repress the p300 HAT dependent transcriptional activation from in vitro assembled chromatin template but had no effect on transcription from DNA. These results suggest that the compounds could be specific to HATs. Thus these compounds should be useful as biological switching molecule for evaluating the role of p300 and PCAF in cellular functions and may be useful as new chemical entities for the development of anticancer drugs.
Owner:JAWAHARLAL NEHRU CENT FOR ADVANCED SCI RES

Reagents and methods for the determination of pk/adme-tox characteristics of new chemical entities and of drug candidates

Methods using colloidal conductive polymers, noble metal nanoparticles or of stable metal / conductive polymer composite colloids as reagents for at least the in vitro prediction of, if not the determination of, PK / ADME-tox properties of new chemical entities (NCEs) are provided. Also provided are kits that include the subject methods and reagents for application thereof. The salient characteristics of these methods and reagents pertaining to the present invention reside in the fact that the reactions in which they are involved are homogeneous, rapid, and proceed as “mix and read” processes.
Owner:PHARMA DIAGNOSTICS

Application of SRGN gene in serving as serum marker for detecting triple-negative breast cancer

The invention discloses application of an SRGN gene and polypeptide thereof in serving as a detection marker for breast cancer molecular typing, in particular to application of the SRGN gene and the polypeptide thereof in serving as a serum marker for detecting a triple-negative breast cancer or in preparation of a detection reagent for the triple-negative breast cancer, and provides a novel breast cancer serum marker, that is, the SRGN gene and the polypeptide thereof. It is proved that expression of the SRGN gene in breast cancer serum is enhanced, and expression of the SRGN gene in serum of a triple-negative breast cancer patient is mainly and significantly increased compared with expression of the SRGN gene in serum of a breast cancer patient with the other molecular types. Accordingly, not only is a new target supplied to breast cancer serology detection, but also new data and a quick serology detection method are supplied to breast cancer molecular typing; a new chemical entity is designed at the gene level and the protein level by taking the gene as the target, breast cancer molecular typing can be quickly, conveniently and effectively performed, and therefore the breast cancer treatment effect is improved.
Owner:CANCER CENT OF GUANGZHOU MEDICAL UNIV

Methods to enhance bioavailability of organic small molecules and deposited films made therefrom

Solid films and articles having a surface with discrete regions patterned with a deposited low molecular weight organic compound, such as pharmaceutical actives and new chemical entities, are provided. The organic compound may be present at >= about 99 mass % in the one or more discrete regions and may be crystalline or amorphous. The deposited organic compound may be deposited as a film having high surface area. The deposited organic compound exhibits enhanced solubility and bioavailability, by way of non-limiting example. Methods of organic vapor jet printing deposition method of such a lowmolecular weight organic compound in an inert gas stream are also provided.
Owner:RGT UNIV OF MICHIGAN

Calmangafodipir, a New Chemical Entity, and Other Mixed Metal Complexes, Methods of Preparation, Compositions, and Methods of Treatment

A mixed metal complex of a compound of Formula I, or a salt thereof, wherein the mixed metals comprise a Group III-XII transition metal and a Group II metal: (Formula I) (I) wherein X, R1, R2, R3, and R4 are as defined herein, is produced in a one step crystallization from a solution of the Group III-XII transition metal, the Group II metal, and a compound of Formula I. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering the mixed metal complex to the patient.
Owner:EGETIS THERAPEUTICS AB

Method for detecting metabolic performance of new chemical entity in different species of liver microsomes

The invention discloses a method for detecting the metabolic performance of a new chemical entity in different species of liver microsomes, which comprises the following steps: in a reaction system containing a buffer solution, liver microsomes, a substrate, MgCl2 and NADPH, screening out an optimal reaction condition by taking the metabolic rate of the substrate as a reference to obtain a human liver microsome incubation system. According to the establishment method of the human liver microsome incubation system, rat, mouse, dog and monkey liver microsome incubation systems are sequentially established. The method comprises the following steps: performing in-vitro metabolism test on a new chemical entity in incubation systems of different species of liver microsomes, performing positive group reaction by using a substrate, and setting a negative group without adding NADPH and a blank group without adding liver microsomes; and identifying a metabolism result after testing. According to the method for detecting the metabolic performance of the new chemical entity in different species of liver microsomes, false positive and false negative results can be avoided, the reliability of an identification result is improved, and a reliable basis is provided for promoting research and development of new drugs.
Owner:安领生物医药(苏州)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products